The Comparative Effectiveness of Rituximab- vs Cyclophosphamide-Based Remission Induction Strategies in ANCA-Associated Vasculitis for the Risk of Kidney Failure and Mortality.
Zachary Scott WallaceXiaoqing FuClaire CookCatherine AholaZachary WilliamsBrett DolinerJennifer S HanbergJohn H StoneYuqing ZhangHyon K ChoiPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
Rituximab- and cyclophosphamide-based remission induction strategies for AAV are associated with similar risks of kidney failure and death.